Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a "chemical knock-out equivalent" to assess the impact of efflux transporters on oral drug absorption in the rat.

Kalgutkar AS, Frederick KS, Chupka J, Feng B, Kempshall S, Mireles RJ, Fenner KS, Troutman MD.

J Pharm Sci. 2009 Dec;98(12):4914-27. doi: 10.1002/jps.21756.

PMID:
19373887
2.

In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.

Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, de Morais SM.

Drug Metab Dispos. 2008 Feb;36(2):268-75. Epub 2007 Oct 25.

PMID:
17962372
3.

Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human.

Kalgutkar AS, Feng B, Nguyen HT, Frederick KS, Campbell SD, Hatch HL, Bi YA, Kazolias DC, Davidson RE, Mireles RJ, Duignan DB, Choo EF, Zhao SX.

Drug Metab Dispos. 2007 Nov;35(11):2111-8. Epub 2007 Aug 8.

PMID:
17686907
4.

Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.

Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA.

Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22.

PMID:
15616150

Supplemental Content

Loading ...
Support Center